Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Quantifying the genetic risk for the development of axial spondyloarthropathy: could this become a diagnostic tool?

Journal article

Wordsworth BP. et al, (2018), Curr opin rheumatol, 30, 319 - 323

INVESTIGATING THE REGULATORY SNPS AT THE RUNX3 LOCUS ASSOCIATED WITH ANKYLOSING SPONDYLITIS

Conference paper

Vecellio ML. et al, (2018), Annals of the rheumatic diseases, 77, 158 - 158

RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis-Novel Targets for Therapy?

Journal article

Vecellio M. et al, (2018), Front immunol, 9

EXPLORING THE ANKYLOSING SPONDYLITIS-ASSOCIATED REGULATORY SNPs AT THE RUNX3 LOCUS

Conference paper

Vecellio M. et al, (2018), Clinical and experimental rheumatology, 36, 734 - 734

Reply to Reeves et al.: No evidence for rare ERAP1 haplotypes and haplotype combinations in ankylosing spondylitis.

Journal article

Wordsworth BP. et al, (2017), Proc natl acad sci u s a, 114

ERAP1 association with ankylosing spondylitis is attributable to common genotypes rather than rare haplotype combinations.

Journal article

Roberts AR. et al, (2017), Proc natl acad sci u s a, 114, 558 - 561

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Journal article

Picaud S. et al, (2015), Cancer res, 75, 5106 - 5119

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Journal article

Hammitzsch A. et al, (2015), Proc natl acad sci u s a, 112, 10768 - 10773

Load More